Kiniksa Pharmaceuticals International, PLC Form 4 insider transactions

Kiniksa Pharmaceuticals' Chief Operating Officer, Eben Tessari, exercised share options and sold a portion of his holdings on December 16, 2024, according to a recent SEC filing.

Kiniksa Pharmaceuticals' CFO, Mark Ragosa, executed multiple share transactions, including sales and option exercises, under a pre-arranged 10b5-1 trading plan.

Kiniksa Pharmaceuticals' Chief Financial Officer, Mark Ragosa, executed a series of stock option exercises and sales under a pre-arranged 10b5-1 trading plan.

A Kiniksa Pharmaceuticals executive, Michael R. Megna, executed share option exercises and sales under a pre-arranged 10b5-1 trading plan.

Kiniksa Pharmaceuticals' Chief Operating Officer, Eben Tessari, executed multiple transactions involving Class A Ordinary Shares and share options, including both acquisitions and disposals, under a pre-arranged 10b5-1 trading plan.

Director Richard S. Levy acquired 1,303 Class A Ordinary Shares of Kiniksa Pharmaceuticals International, plc through the vesting of Restricted Share Units on November 7, 2024.

Sanj K. Patel, Chairman and CEO of Kiniksa Pharmaceuticals International, exercised stock options and sold shares under a pre-arranged 10b5-1 trading plan.

Eben Tessari, Chief Operating Officer of Kiniksa Pharmaceuticals International, sold 17,000 Class A Ordinary Shares on October 15, 2024, under a pre-arranged 10b5-1 trading plan.

Michael R. Megna, Chief Accounting Officer of Kiniksa Pharmaceuticals International, plc, reports the vesting and subsequent disposal of Class A Ordinary Shares to cover tax obligations.

Baker Bros. Advisors and related entities report changes in beneficial ownership of Kiniksa Pharmaceuticals International, plc, including the grant of restricted share units and share options to a new board member, M. Cantey Boyd, and adjustments due to a redomiciliation transaction.

Kiniksa Pharmaceuticals' Chief Operating Officer, Tessari Eben, exercised stock options and sold shares under a pre-arranged 10b5-1 trading plan.

Michael R. Megna, Chief Accounting Officer of Kiniksa Pharmaceuticals International, plc, reports acquisition and disposal of Class A Ordinary Shares and Restricted Share Units.

Sanj K Patel, Chairman and CEO of Kiniksa Pharmaceuticals International, plc, reports acquisition and disposal of Class A Ordinary Shares and Restricted Share Units.

Eben Tessari, Chief Operating Officer of Kiniksa Pharmaceuticals International, plc, reports acquisition and disposal of Class A Ordinary Shares and Restricted Share Units.

John F. Paolini, Chief Medical Officer of Kiniksa Pharmaceuticals International, plc, reports multiple transactions involving Class A Ordinary Shares and Restricted Share Units.

Chief Financial Officer Mark Ragosa reports acquisition and disposal of Kiniksa Pharmaceuticals International, plc shares and derivative securities.

Chief Commercial Officer Ross Moat reports acquisition and disposal of Kiniksa Pharmaceuticals International, plc shares, including transactions under a 10b5-1 plan.

Chief Operating Officer Eben Tessari exercised options and sold shares of Kiniksa Pharmaceuticals International, plc on August 27, 2024, according to a Form 4 filing.

Sanj K. Patel, Chairman and CEO of Kiniksa Pharmaceuticals International, plc, reports multiple transactions involving Class A Ordinary Shares, including acquisitions via option exercise and sales under a pre-arranged 10b5-1 trading plan.

Mark Ragosa, CFO of Kiniksa Pharmaceuticals International, plc, sold 24,248 Class A Ordinary Shares at $24.79 and exercised options to acquire 24,248 shares at $11.10 on July 23, 2024, according to a Form 4 filing.

John F. Paolini, Chief Medical Officer of Kiniksa Pharmaceuticals International, plc, executed sales of Class A Ordinary Shares on July 23, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Director Bradley Cole reports acquisition of stock options and vesting of restricted share units (RSUs) in Kiniksa Pharmaceuticals.

Director Richard S. Levy reports acquisition and disposal of Class A Common Shares and derivative securities in Kiniksa Pharmaceuticals.

Director Thomas Malley reports transactions involving Kiniksa Pharmaceuticals Class A Common Shares and Restricted Share Units.

Director Tracey L. McCain reports acquisition and disposal of Kiniksa Pharmaceuticals shares and options, including restricted share units (RSUs) vesting.

Director Kimberly J. Popovits reports acquisition of Kiniksa Pharmaceuticals shares and options, including restricted share units, as per Form 4 filing.

Director Barry D Quart reports transactions involving Kiniksa Pharmaceuticals Class A Common Shares and Restricted Share Units.

Baker Bros. Advisors and related entities report changes in their beneficial ownership of Kiniksa Pharmaceuticals, including the acquisition of restricted stock units and share options.

Director Richard S. Levy reports transactions involving Kiniksa Pharmaceuticals Class A Common Shares and Restricted Share Units on May 3, 2024.

Chief Financial Officer Mark Ragosa of Kiniksa Pharmaceuticals, Ltd. reports the acquisition and disposal of Class A Common Shares and Restricted Share Units.